Matricelf's FDA Nod: A Calculated Step on the Path to Repairing Spinal Cord Injury

NESS ZIONA, Israel – September 03, 2026 – In the high-stakes world of regenerative medicine, where breakthroughs are rare and setbacks are common, a green light from regulators can feel like a seismic event. Matricelf Ltd., an Israeli biotech firm, just received such a signal from the U.S. Food and Drug Administration (FDA) for its spinal cord injury program, NewRal. The agency provided supportive written feedback on key elements of a proposed first-in-human clinical trial, moving a potentially revolutionary therapy one step closer to reality.

While the news marks a significant milestone, it also illuminates the perilous and capital-intensive journey from laboratory concept to clinical application. For the roughly 310,000 people living with spinal cord injuries (SCI) in the U.S. alone, progress can't come fast enough. Yet the path is paved with scientific, regulatory, and financial hurdles that have stymied countless predecessors.

Matricelf's announcement confirmed that the FDA's Center for Biologics Evaluation and Research (CBER) expressed agreement with the core design of its initial human trial. This includes the target patient population—adults with chronic, complete traumatic thoracic spinal cord injuries—and the trial's structure as a single-arm, open-label study focused primarily on safety. The feedback provides a critical piece of actionable intelligence for the company as it prepares a formal Investigational New Drug (IND) application.

"The FDA's agreement with key elements of our proposed first in human trial... gives us valuable regulatory guidance as we prepare for a future IND submission," said Gil Hakim, Chief Executive Officer of Matricelf. "We will now incorporate the FDA's comments and continue advancing NewRal toward the clinic."

The Science of Personalized Repair

What sets NewRal apart in a growing field of SCI research is its deeply personalized approach. The therapy is not an off-the-shelf drug but an autologous, engineered neural tissue transplant. In simple terms, it's a living 'patch' for the spinal cord, built from the patient's own biological materials.

The process begins with two samples from the patient: a blood draw and a small piece of omentum, a fatty tissue in the abdomen. The blood cells are reprogrammed into induced pluripotent stem cells (iPSCs), a Nobel Prize-winning technology that allows mature cells to be reverted to a stem-cell-like state. Simultaneously, the omentum tissue is decellularized, leaving behind a natural, patient-specific scaffolding known as an extracellular matrix (ECM). This ECM is processed into a hydrogel.

Within this personalized hydrogel scaffold, the patient's iPSCs are cultured and guided to differentiate into a three-dimensional network of functional neural tissue. The resulting implant, containing synchronized neuronal connections, is designed to be surgically placed at the injury site to bridge the gap in the damaged spinal cord. By using the patient's own cells and tissue matrix, Matricelf aims to bypass the risk of immune rejection, a major obstacle for many cell-based therapies. This strategy represents a fundamental shift from merely managing symptoms or modulating the injury environment to actively rebuilding the lost tissue.

Navigating the Regulatory Gauntlet

The FDA's feedback, delivered through a 'Written Response Only' (WRO) interaction, is a crucial de-risking event. It provides a clearer roadmap for the IND submission, which is the comprehensive data package required to secure permission for human trials. However, it is far from a final approval. The agency's feedback was based on a limited synopsis, and the full IND application will face far more intensive scrutiny.

The FDA has already requested additional details, including the establishment of clear trial stopping rules, objective patient discharge criteria, and more specifics on the surgical procedure. This is standard for a therapy of this complexity and highlights the agency's focus on safety in this initial phase. While Matricelf's proposed efficacy measures—designed to evaluate neurological changes and functional independence—were deemed acceptable as exploratory endpoints, the primary goal of this first trial will be to prove that the therapy is safe and tolerable.

Bringing a regenerative medicine therapy to market is a marathon that can take 10 to 15 years and cost billions. The FDA has established expedited pathways like the Regenerative Medicine Advanced Therapy (RMAT) designation to help accelerate promising treatments, and while the field is seeing momentum with a record number of approvals in recent years, the scientific and manufacturing complexities remain immense. For NewRal, scaling its highly personalized manufacturing process will be a key challenge on the path to commercialization.

A Crowded Field and a $30 Billion Problem

Matricelf is entering a competitive but desperately needed market. Spinal cord injury imposes an estimated annual economic burden of $30 billion in the U.S., with lifetime costs per patient reaching as high as $6 million. The current standard of care—focused on surgical stabilization, rehabilitation, and symptom management—offers little hope for restoring lost function.

This vast unmet need has attracted a diverse array of competitors. Lineage Cell Therapeutics is advancing its own stem cell therapy, AST-OPC1. Companies like NervGen Pharma are developing drugs designed to promote nerve repair by overcoming natural inhibitors to regeneration. Meanwhile, the field of neuromodulation is making strides with devices that use electrical stimulation to enhance motor function. Matricelf is betting that its unique tissue-engineering approach, focused on fundamental restoration, will ultimately provide a more definitive solution than therapies that modulate the body's existing response to injury.

The High-Stakes Financial Gamble

For a preclinical company like Matricelf, positive regulatory news is more than a scientific validation; it's a financial lifeline. Trading on the Tel Aviv Stock Exchange with a market capitalization under $10 million and a cash runway of less than a year based on recent trends, the company operates in a high-risk financial environment. Its stock has been highly volatile, reflecting the binary nature of biotech investing.

The FDA's feedback serves as a powerful signal to current and potential investors that the company's lead program is on a viable regulatory track. This is critical as Matricelf executes its strategy, which includes completing its preclinical program and preparing for the first human implantation in 2027. Success in these endeavors will be essential for future fundraising and a potential Nasdaq listing the company is eyeing for 2027, which would open access to a much larger pool of capital.

Recognizing these challenges, Matricelf has made strategic moves to bolster investor confidence, including appointing Ron Mayron, the former CEO of Teva Israel, as its active Chairman. This blend of promising science and experienced leadership will be essential as the company navigates the long and expensive road ahead, where the promise of healing is matched only by the risk of failure.